Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Guselkumab/methotrexate/tozinameran
Apremilast/guselkumab/methotrexate
Guselkumab zugelassen
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
Acitretin/Guselkumab
Atezolizumab/guselkumab
Guselkumab/ixekizumab
Brodalumab/guselkumab/risankizumab
Brodalumab/Guselkumab/Ustekinumab
